Kodiak Sciences Inc (KOD)
3.18
+0.16
(+5.30%)
USD |
NASDAQ |
May 31, 16:00
3.18
0.00 (0.00%)
Pre-Market: 20:00
Kodiak Sciences Cash from Financing (Quarterly): 0.038M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.038M |
December 31, 2023 | -0.124M |
September 30, 2023 | -0.012M |
June 30, 2023 | 0.17M |
March 31, 2023 | -0.003M |
December 31, 2022 | 0.097M |
September 30, 2022 | 0.078M |
June 30, 2022 | 0.054M |
March 31, 2022 | 1.666M |
December 31, 2021 | 2.157M |
September 30, 2021 | 2.031M |
June 30, 2021 | 2.522M |
March 31, 2021 | 1.472M |
Date | Value |
---|---|
December 31, 2020 | 616.28M |
September 30, 2020 | 0.804M |
June 30, 2020 | 0.504M |
March 31, 2020 | 99.79M |
December 31, 2019 | 299.34M |
September 30, 2019 | 0.285M |
June 30, 2019 | 0.015M |
March 31, 2019 | 0.047M |
December 31, 2018 | 85.53M |
September 30, 2018 | -1.049M |
June 30, 2018 | -0.686M |
March 31, 2018 | 32.68M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.124M
Minimum
Dec 2023
616.28M
Maximum
Dec 2020
51.36M
Average
0.3945M
Median
Cash from Financing (Quarterly) Benchmarks
Avalo Therapeutics Inc | 108.61M |
Regeneron Pharmaceuticals Inc | 47.10M |
Ligand Pharmaceuticals Inc | 12.18M |
iBio Inc | 5.025M |
Dare Bioscience Inc | 0.014M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -39.60M |
Cash from Investing (Quarterly) | -0.166M |
Free Cash Flow | -175.76M |
Free Cash Flow Per Share (Quarterly) | -0.7546 |
Free Cash Flow Yield | -105.4% |